Trials / Completed
CompletedNCT02173249
A Single-Center, Open-Label, Study of the Plasma Pharmacokinetics and Safety of AC-170 0.24%
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- Aciex Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the Plasma Pharmacokinetics and Safety of AC 170 0.24% in Healthy, Adult Subjects when used twice daily for one week.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AC 170 0.24% | 1 drop in each eye 2 times daily for 1 week |
Timeline
- Start date
- 2014-06-01
- Primary completion
- 2014-08-01
- Completion
- 2014-08-01
- First posted
- 2014-06-24
- Last updated
- 2017-09-14
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02173249. Inclusion in this directory is not an endorsement.